The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Subscribe To Our Newsletter & Stay Updated
